These results suggest that anti-VEGF therapy for CRC may be better targeted to patients with significant excess of proangiogenic isoforms over antiangiogenic isoforms, and that therapies that specifically target the proangiogenic isoforms may be more effective. Here, VEGFA is linked to colorectal carcinoma.